Emergent BioSolutions Inc. (NYSE:EBS) Stock Position Reduced by Values First Advisors Inc.

Values First Advisors Inc. lowered its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 17.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 376,692 shares of the biopharmaceutical company's stock after selling 79,516 shares during the period. Emergent BioSolutions makes up approximately 2.0% of Values First Advisors Inc.'s portfolio, making the stock its 8th largest position. Values First Advisors Inc. owned approximately 0.70% of Emergent BioSolutions worth $3,601,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in EBS. State Street Corp grew its position in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock worth $15,960,000 after purchasing an additional 1,713,200 shares during the period. Oak Hill Advisors LP bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at $9,296,000. Assenagon Asset Management S.A. grew its position in shares of Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company's stock valued at $6,192,000 after acquiring an additional 316,700 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of Emergent BioSolutions during the 4th quarter valued at $1,831,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at $1,547,000. Institutional investors own 78.40% of the company's stock.

Analyst Upgrades and Downgrades

EBS has been the subject of a number of recent research reports. Benchmark boosted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. StockNews.com downgraded shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Friday, January 24th. Finally, HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, January 21st.

Emergent BioSolutions Price Performance

Shares of EBS traded up $0.20 during trading hours on Friday, reaching $9.70. 695,038 shares of the stock traded hands, compared to its average volume of 890,394. The company has a market cap of $525.28 million, a P/E ratio of -2.36 and a beta of 1.62. Emergent BioSolutions Inc. has a 52-week low of $1.48 and a 52-week high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company's 50-day moving average price is $9.69 and its two-hundred day moving average price is $9.17.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.